2022 World Conference on Lung Cancer (ePosters)-EP16.02-011. Liquid Biopsies in the Setting of Early-Stage Lung Cancer for the Detection of Actionable Mutations

EP16.02-011. Liquid Biopsies in the Setting of Early-Stage Lung Cancer for the Detection of Actionable Mutations

Pdf Summary

This study aimed to evaluate the usefulness of liquid biopsies for the detection of actionable mutations in early-stage lung cancer. The researchers collected liquid biopsies at different timepoints and compared the yield of cfDNA obtained. They found that the maximum yield of cfDNA was obtained at the surgical discharge timepoint. However, these liquid biopsies proved unsuitable for the detection of actionable mutations, as the somatic mutations identified in tissue biopsies could not be detected. The researchers concluded that while the amount of cfDNA is maximized at surgical discharge, its most likely origin is not tumor-related but rather the traumatic and inflammatory events associated with the surgical procedure. On the other hand, when they sequenced the liquid biopsies of patients with actionable mutations in tissue biopsies, they found the expected mutation in the pre-operatory timepoint. However, the mutation allele fraction detected was consistently very low. Overall, the researchers concluded that the pre-operatory timepoint is the most suitable for the detection of actionable mutations in early-stage lung cancer.

Asset Subtitle

Joana Espiga de Macedo

Meta Tag

Speaker Joana Espiga de Macedo

Topic Tumour Biology and Biomarkers - Minimally Invasive Biomarkers

Keywords

liquid biopsies

actionable mutations

early-stage lung cancer

cfDNA

yield

surgical discharge

tissue biopsies

somatic mutations

pre-operatory timepoint

mutation allele fraction